News of Note—Gardasil-Cervarix divide, flu vaccines and more

newspapers
(Pixabay)

Here is some other vaccine news of note for the week:

> Starting from this fall, students in Quebec are receiving one shot of Merck & Co.’s Gardasil 9 and then later a shot of GlaxoSmithKline’s Cervarix to protect against HPV. Experts worry the new program will not build sufficient immunity to seven of the nine strains not covered in Cervarix. The Globe and Mail article

> Italy’s health minister, Giulia Grillo, from the vaccine-skeptic party Five Star Movement, has sacked the entire board of the country’s health advisory committee. The Guardian article

> An ongoing shortage of GlaxoSmithKline’s popular shingles vaccine, Shingrix, has caused frustration among people waiting to get it. The Boston Globe article

> About 60% of people 60 and older in the U.S. have gotten a flu shot this season, according to new data from Clover Health. UPI article

> The global vaccines market is expected to reach $57.5 billion by 2025, up from from $33.7 billion in 2018, according to a report from Meticulous Research. Release

Suggested Articles

GSK has formed several collaborations across the globe that will use its AS03 adjuvant to develop vaccines against the novel coronavirus.

Former FDA Commissioner Scott Gottlieb says 40% of the population needs to be vaccinated to achieve COVID-19 herd immunity.

CanSino Bio, Moderna and a collaboration between Oxford Univeristy and AstraZeneca are frontrunners, but they all face hurdles shared and unique.